Salary Day Investing — June 2026: Down 1.8%, But Still in the Green

 Salary in. Transfer done. Shares bought.

June wasn't a great month. I'll be honest about that upfront.

The portfolio dropped 1.8% this month, pulling my overall return down from +2.22% to +0.96%. That thin green line is hanging on — but only just.

When I saw the numbers, I felt a little flat. Not panicked. Just… deflated. You build something up slowly over months, and then one rough month quietly takes a chunk of it back.

But the plan doesn't change because the mood does.


June Portfolio Breakdown

Stock    Opening    Closing    Change
BRK.B    $474.48    $500.39    +5.46%
JEPQ    $61.15        $61.46    +0.51%
O    $61.28    $61.96    +1.11%
QQQ    $738.31    $736.40    -0.26%
VOO    $695.59    $686.81    -1.26%
SCHD    $32.50    $31.71    -2.43%
NVDA    $211.14    $200.09    -5.23%

The standout this month was BRK.B, up 5.46%. Warren Buffett's company quietly did its thing — steady, reliable, no drama. Exactly what I need in a volatile month.

The weak link was NVDA, down 5.23%. AI-related stocks pulled back broadly in June, and NVDA wasn't spared. I knew going in that it would be volatile. Knowing that intellectually and watching it drop in real time are two different experiences. It still stings a little.

VOO and SCHD followed the broader market lower — nothing alarming, just the natural rhythm of markets doing what markets do.


New Addition: XLV

This month I officially added XLV — the Health Care Select Sector SPDR Fund — to the portfolio.

As a pharmacist who has spent years working in healthcare, buying XLV carries a meaning that's hard to explain to someone outside the industry.

During the day, I help patients understand their medications. In the evenings, I'm a small shareholder in the companies that make those medications.

XLV holds the largest healthcare companies in the S&P 500 — UnitedHealth, Johnson & Johnson, Eli Lilly, AbbVie, Merck. These aren't exciting growth stocks. They're the infrastructure of global healthcare.

And here's what I know from working in this industry: people don't stop getting sick when the economy slows down. Demand for healthcare is one of the most durable forces in any economy. An ageing global population only makes that more true over time.

For a dividend investor, that's a tailwind worth owning.


June Dividend Income

StockDividend
O$0.08
XLV$0.08
NVDA$0.03
Total$0.19

The portfolio was down. The dividends still arrived.

XLV paid its first dividend — $0.08 — the same week I added it to the portfolio. NVDA quietly dropped $0.03 as well. Small amounts, but the cash flow is widening.

Last month my total dividend income was $0.08. This month it's $0.19. That's more than double, just from adding new positions and reinvesting consistently.

The compounding is slow. But it's moving.


How I'm Thinking About This Month

June's results weren't what I hoped for.

But I keep coming back to the same question: has anything changed about why I own these positions?

NVDA is still the dominant AI chip company. VOO still tracks the S&P 500. SCHD still holds decades-long dividend growers. BRK.B is still Berkshire Hathaway.

Nothing in the underlying businesses changed. Only the price did.

And when prices fall, the same monthly transfer buys more shares. That's not a silver lining I'm forcing — it's just how dollar-cost averaging works.

I don't enjoy down months. But I've stopped being surprised by them.


Wrapping Up

June: portfolio down 1.8%. Overall return: +0.96%. Dividend income: $0.19, all reinvested.

XLV joins the portfolio. The income streams grow a little wider.

Same plan next month. Same transfer. Same purchases. One paycheck at a time.

Comments

Popular posts from this blog

SpaceX Is Going Public — Should I Buy?

Korea's Stock Market Crashed 10% Yesterday. My Dividend Still Arrived.

$0.08. That's What I Received This Month — And It Changed How I Think About Everything